Literature DB >> 10404334

In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes.

L Martínez-Martínez1, A Pascual, A I Suárez, E J Perea.   

Abstract

The objective of this study was to evaluate the in-vitro activity of levofloxacin, ofloxacin and D-ofloxacin compared with ciprofloxacin, norfloxacin and sparfloxacin against coryneform bacteria and Listeria monocytogenes isolated from clinical samples. The following organisms (and number of strains) were studied: Corynebacterium jeikeium (20), Corynebacterium urealyticum (20), Corynebacterium minutissimum (20), Corynebacterium striatum (20), Corynebacterium amycolatum (30), Brevibacterium spp. (15) and Listeria monocytogenes (15). Antimicrobial activity was determined by microdilution using cation-adjusted Mueller-Hinton broth supplemented with 0.5% Tween 80 when testing C. jeikeium or C. urealyticum. Fluoroquinolones were used in the range 0.015-16 mg/L. Plates were incubated in air at 35 degrees C for 18-20 h (24 h when testing C. jeikeium or C. urealyticum). The following MIC50 values were obtained for all 140 organisms tested: levofloxacin, 1 mg/L; ofloxacin, 2 mg/L; D-ofloxacin, > 16 mg/L; ciprofloxacin, 1 mg/L; norfloxacin, 16 mg/L; sparfloxacin, 1 mg/L. MIC90 values were > 16 mg/L for all test antibiotics with the exception of levofloxacin, which had an MIC90 value of 16 mg/L. At a concentration of 2 mg/L, levofloxacin inhibited all L. monocytogenes strains and 35-93% of the remaining species. MIC90 values of ofloxacin were one dilution step higher than those of levofloxacin against C. minutissimum, C. striatum, Brevibacterium spp. and L. monocytogenes. Levofloxacin showed similar (C. jeikeium, C. urealyticum, C. amycolatum and Brevibacterium spp.) or greater (C. minutissimum and C. striatum) activity than ciprofloxacin and sparfloxacin, and higher than D-ofloxacin or norfloxacin against all species studied. In conclusion, levofloxacin was the most active of the six fluoroquinolones evaluated against coryneform bacteria isolated from clinical samples and could therefore be a promising treatment option in this setting.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404334     DOI: 10.1093/jac/43.suppl_3.27

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.

Authors:  L Martínez-Martínez; P Joyanes; A I Suárez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum.

Authors:  Josep M Sierra; Luis Martinez-Martinez; Fernando Vázquez; Ernest Giralt; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 4.  Update on Listeria monocytogenes infection.

Authors:  Nancy F Crum
Journal:  Curr Gastroenterol Rep       Date:  2002-08

5.  Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.

Authors:  Carlos Salas; Jorge Calvo; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

6.  Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.

Authors:  María del Carmen Conejo; Luis Martínez-Martínez; Alvaro Pascual; Ana Isabel Suárez; Evelio J Perea
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 7.  Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.

Authors:  Els Van de Perre; Gina Reichman; Deborah De Geyter; Caroline Geers; Karl M Wissing; Emmanuel Letavernier
Journal:  Front Med (Lausanne)       Date:  2021-01-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.